CAPRICOR THERAPEUTICS INC (CAPR) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:CAPR • US14070B3096

23.03 USD
-1.47 (-6%)
At close: Feb 5, 2026
22.5981 USD
-0.43 (-1.88%)
After Hours: 2/5/2026, 4:41:01 PM
Fundamental Rating

4

Overall CAPR gets a fundamental rating of 4 out of 10. We evaluated CAPR against 524 industry peers in the Biotechnology industry. While CAPR has a great health rating, there are worries on its profitability. CAPR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CAPR has reported negative net income.
  • In the past year CAPR has reported a negative cash flow from operations.
  • CAPR had negative earnings in each of the past 5 years.
  • CAPR had negative operating cash flow in 4 of the past 5 years.
CAPR Yearly Net Income VS EBIT VS OCF VS FCFCAPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -64.85%, CAPR is in line with its industry, outperforming 40.08% of the companies in the same industry.
  • CAPR's Return On Equity of -97.76% is in line compared to the rest of the industry. CAPR outperforms 46.95% of its industry peers.
Industry RankSector Rank
ROA -64.85%
ROE -97.76%
ROIC N/A
ROA(3y)-39.87%
ROA(5y)-41.5%
ROE(3y)-124.19%
ROE(5y)-96.97%
ROIC(3y)N/A
ROIC(5y)N/A
CAPR Yearly ROA, ROE, ROICCAPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

  • CAPR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAPR Yearly Profit, Operating, Gross MarginsCAPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • CAPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CAPR has been increased compared to 1 year ago.
  • The number of shares outstanding for CAPR has been increased compared to 5 years ago.
  • The debt/assets ratio for CAPR has been reduced compared to a year ago.
CAPR Yearly Shares OutstandingCAPR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CAPR Yearly Total Debt VS Total AssetsCAPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • CAPR has an Altman-Z score of 11.26. This indicates that CAPR is financially healthy and has little risk of bankruptcy at the moment.
  • CAPR has a Altman-Z score of 11.26. This is amongst the best in the industry. CAPR outperforms 83.59% of its industry peers.
  • There is no outstanding debt for CAPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.26
ROIC/WACCN/A
WACC8.91%
CAPR Yearly LT Debt VS Equity VS FCFCAPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • CAPR has a Current Ratio of 3.59. This indicates that CAPR is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.59, CAPR perfoms like the industry average, outperforming 42.94% of the companies in the same industry.
  • A Quick Ratio of 3.59 indicates that CAPR has no problem at all paying its short term obligations.
  • CAPR has a Quick ratio of 3.59. This is comparable to the rest of the industry: CAPR outperforms 45.04% of its industry peers.
Industry RankSector Rank
Current Ratio 3.59
Quick Ratio 3.59
CAPR Yearly Current Assets VS Current LiabilitesCAPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The earnings per share for CAPR have decreased strongly by -69.81% in the last year.
  • CAPR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -52.08%.
  • CAPR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 85.64% yearly.
EPS 1Y (TTM)-69.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.11%
Revenue 1Y (TTM)-52.08%
Revenue growth 3Y352.73%
Revenue growth 5Y85.64%
Sales Q2Q%-100%

3.2 Future

  • CAPR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.19% yearly.
  • Based on estimates for the next years, CAPR will show a very strong growth in Revenue. The Revenue will grow by 90.58% on average per year.
EPS Next Y-83.41%
EPS Next 2Y-14.49%
EPS Next 3Y27.38%
EPS Next 5Y35.19%
Revenue Next Year-96.42%
Revenue Next 2Y142.38%
Revenue Next 3Y101.72%
Revenue Next 5Y90.58%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CAPR Yearly Revenue VS EstimatesCAPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
CAPR Yearly EPS VS EstimatesCAPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 -10 15

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CAPR. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CAPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CAPR Price Earnings VS Forward Price EarningsCAPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAPR Per share dataCAPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • CAPR's earnings are expected to grow with 27.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.49%
EPS Next 3Y27.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CAPR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CAPRICOR THERAPEUTICS INC

NASDAQ:CAPR (2/5/2026, 4:41:01 PM)

After market: 22.5981 -0.43 (-1.88%)

23.03

-1.47 (-6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-17
Inst Owners32.19%
Inst Owner Change2.89%
Ins Owners1.16%
Ins Owner Change0.02%
Market Cap1.05B
Revenue(TTM)11.13M
Net Income(TTM)-81.99M
Analysts83.75
Price Target51.82 (125.01%)
Short Float %13.42%
Short Ratio1.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.94%
Min EPS beat(2)-19.18%
Max EPS beat(2)3.3%
EPS beat(4)2
Avg EPS beat(4)-9.88%
Min EPS beat(4)-64.08%
Max EPS beat(4)40.43%
EPS beat(8)4
Avg EPS beat(8)-16.23%
EPS beat(12)8
Avg EPS beat(12)-6.77%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-51.98%
Min Revenue beat(4)-100%
Max Revenue beat(4)92.08%
Revenue beat(8)3
Avg Revenue beat(8)-34.76%
Revenue beat(12)7
Avg Revenue beat(12)1598.21%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)146.6%
EPS NQ rev (1m)-5.65%
EPS NQ rev (3m)-1.41%
EPS NY rev (1m)0%
EPS NY rev (3m)1.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-54.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 94.6
P/FCF N/A
P/OCF N/A
P/B 12.55
P/tB 12.55
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-1.57
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.34
OCFYN/A
SpS0.24
BVpS1.83
TBVpS1.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -64.85%
ROE -97.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.87%
ROA(5y)-41.5%
ROE(3y)-124.19%
ROE(5y)-96.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 416.19%
Cap/Sales 65.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.59
Quick Ratio 3.59
Altman-Z 11.26
F-Score2
WACC8.91%
ROIC/WACCN/A
Cap/Depr(3y)311.17%
Cap/Depr(5y)361.27%
Cap/Sales(3y)48.94%
Cap/Sales(5y)164.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-69.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.11%
EPS Next Y-83.41%
EPS Next 2Y-14.49%
EPS Next 3Y27.38%
EPS Next 5Y35.19%
Revenue 1Y (TTM)-52.08%
Revenue growth 3Y352.73%
Revenue growth 5Y85.64%
Sales Q2Q%-100%
Revenue Next Year-96.42%
Revenue Next 2Y142.38%
Revenue Next 3Y101.72%
Revenue Next 5Y90.58%
EBIT growth 1Y-139.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-127.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-191.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-192.06%
OCF growth 3YN/A
OCF growth 5YN/A

CAPRICOR THERAPEUTICS INC / CAPR FAQ

What is the fundamental rating for CAPR stock?

ChartMill assigns a fundamental rating of 4 / 10 to CAPR.


What is the valuation status of CAPRICOR THERAPEUTICS INC (CAPR) stock?

ChartMill assigns a valuation rating of 1 / 10 to CAPRICOR THERAPEUTICS INC (CAPR). This can be considered as Overvalued.


What is the profitability of CAPR stock?

CAPRICOR THERAPEUTICS INC (CAPR) has a profitability rating of 1 / 10.